Uncategorised - European Medical Journal

Obstructive Sleep Apnoea Associated with Higher Suicide Attempts

A nationwide study from South Korea has found a concerning link between obstructive sleep apnea and suicidal behaviors.

New AI Model Enhances MRI Segmentation for Medical Applications

A groundbreaking automated MRI segmentation model has been developed to provide accurate and robust segmentation of major anatomical structures across all MRI sequences.

Unraveling the Genetic and Phenotypic Complexity of Psychosis in Epilepsy

Explore how genetic and phenotypic features of psychosis in epilepsy can guide precision medicine.

Gender and Age Affect Bleeding Risk in Anticoagulant Treatment

Bleeding risk from anticoagulants varies by gender and age in venous thromboembolism treatment, especially during the initial phase.

Leisure-Time Exercise Linked to Lower Risk of Type 2 Diabetes, Study Finds

Study shows that engaging in moderate to vigorous physical activity during leisure time is associated with a reduced risk of Type 2 diabetes.

Vitamin E Compound Enhances Tumour Immunology and Treatment

The ability to pharmacologically degrade fat mass and obesity-associated protein represents a promising avenue for enhancing anti-tumour immunity.

Tramadol and Parkinson’s: New Pain Insights

Patients with Parkinson’s disease (PD) are five times more likely to experience chronic pain than their age-matched peers, according to a new study analyzing electronic medical records from over 250 million patients.

Integrative Sleep Medicine Enhances Cancer Care: MCM 2025

Integrative sleep medicine is revolutionizing cancer care, as highlighted at the 21st Annual Miami Cancer Meeting (MCM) in Tampa, Florida, this January.

New mRNA Vaccine Boosts TB Protection

A novel lipid nanoparticle (LNP)-mRNA vaccine has demonstrated strong immune responses and enhanced protection against Mycobacterium tuberculosis, the leading cause of infectious mortality worldwide.

The world

EMA grants accelerated review to Gilead’s PrEP drug

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.